Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report

BACKGROUNDSporadic cases of rheumatoid arthritis (RA) due to unsatisfactory responses to Abatacept (ABT) have been reported; however, the rescue therapy has not been finalized. Here, we present a case with difficult-to-treat RA (D2T RA) that was resistant to either a single ABT or a Janus kinase (JA...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of clinical cases Vol. 11; no. 11; pp. 2474 - 2481
Main Authors Qi, Jia-Ping, Jiang, Huan, Wu, Teng, Zhang, Yuan, Huang, Wei, Li, Yi-Xuan, Wang, Jing, Zhang, Ju, Ying, Zhen-Hua
Format Report
LanguageEnglish
Published 16.04.2023
Online AccessGet full text

Cover

More Information
Summary:BACKGROUNDSporadic cases of rheumatoid arthritis (RA) due to unsatisfactory responses to Abatacept (ABT) have been reported; however, the rescue therapy has not been finalized. Here, we present a case with difficult-to-treat RA (D2T RA) that was resistant to either a single ABT or a Janus kinase (JAK) inhibitor (Tofacitinib), but improved with a combination of ABT and JAK inhibitor (Baricitinib, BAT). CASE SUMMARYA 46-year-old Chinese woman who had RA for ten years that was resistant to Tocilizumab, Etanercept, Adalimumab, and ABT. According to the European League Against Rheumatism definition, the patient was diagnosed with D2T RA. It was then improved with a combination of ABT and a JAK inhibitor BAT. CONCLUSIONABT combined with BAT may be an acceptable strategy for treating D2T RA.
Bibliography:ObjectType-Case Study-2
content type line 59
SourceType-Reports-1
ObjectType-Report-1
ISSN:2307-8960
2307-8960
DOI:10.12998/wjcc.v11.i11.2474